← Leaderboards
Bart Ferket
Icahn School Of Medicine At Mount Sinai
$2,024,083
Attributed
$2,024,083
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $684.5K · FY2021–23$1M$750K$500K$250K$0
'21
'22
'23
Funding mix
By agency
NIH$2,024,083 · 1
By mechanism
R01$2,024,083 · 1
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Chung Yin Kong$10,200,842
- Brian Iacoviello$983,177
- Joel Stein$2,463,015
- Juan P Wisnivesky$34,328,417
- Keith Magnus Sigel$6,937,762
Others in their field
Other Emerging Leaders on “Adoption”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- April Brinkoetter · Hungry Heart Media, Inc.$57,302,265
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$28,235,661
- Kathleen Maletic Neuzil · Emory University$26,258,144
- Abraham Aizer Brody · New York University School Of Medicine$24,513,574
Research focus
AdoptionAdherenceAdverse Drug ReactionAffectAdultAlgorithmsAlternative TreatmentAmericanAmputationAtherosclerosisAtherosclerosis RiskAgonistBenchmarkingCardiovascular Disorder PreventionCardiovascular Disorder RiskCardiovascular Risk FactorCardiovascular SystemCaringCause Of DeathCessation Of LifeChronic Kidney FailureClinical PracticeClinical Practice GuidelineCohort
Grant awards (3)
Clinical and economic value of novel diabetes medications for prevention of cardiovascular disease in type 2 diabetes$684,540
R01 · FY2023 · HL · contact PI
Clinical and economic value of novel diabetes medications for prevention of cardiovascular disease in type 2 diabetes$682,248
R01 · FY2022 · HL · contact PI
Clinical and economic value of novel diabetes medications for prevention of cardiovascular disease in type 2 diabetes$657,295
R01 · FY2021 · HL · contact PI